LOGIN
Zoledronic acid improves health-related quality of life in patients with hip fractures
December 2013
Zoledronic acid improves health-related quality of life in patients with hip fractures
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial
Osteoporos Int. 2011 Sep;22(9):2539-49. doi: 10.1007/s00198-010-1514-9. Epub 2011 Jan 20Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
2,127 patients were randomized to assess the benefits of zoledronic acid (ZOL) on health-related quality of life among patients from The Health Outcomes and Reduced Incidence With Zoledronic Acid One Yearly Recurrent Fracture Trial (HORIZON-RFT). Patients received annual infusion of either ZOL 5 mg or placebo within 90 days following surgical repair of low-trauma hip fracture. The end of the study...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.